or Try an Advanced Search...

    ETF Components for FMED - Fidelity Disruptive Medicine ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    BSX A 0.99 6.26
    UNH B -0.15 4.70
    PODD B -1.11 4.44
    ISRG A 0.50 4.42
    DHR D -0.76 3.80
    ARGX A -0.41 3.27
    REGN F -0.19 3.26
    ALNY D 0.24 2.90
    SYK A 0.48 2.73
    EXAS D 1.47 2.72
    PEN B -0.48 2.64
    LFST C 0.07 2.41
    VEEV C 1.07 2.18
    MASI B 1.61 2.01
    LEGN D -0.57 1.95
    EW C 0.60 1.95
    INSP F -0.04 1.92
    DXCM C -1.08 1.88
    TMO D -0.65 1.87
    LLY F -1.80 1.78
    PRCT B 1.39 1.65
    ZLAB C -2.06 1.54
    AGL F 3.59 1.43
    GKOS A 0.87 1.42
    RGEN D -0.47 1.34
    PRVA C -0.53 1.34
    KROS D -0.54 1.34
    JANX C -3.14 1.32
    RMD C -0.23 1.30
    CRNX B -0.35 1.23
    CYTK D -1.72 1.19
    XENE D 1.75 1.17
    DOCS C -2.10 1.14
    DYN D -1.53 1.13
    PCVX D 1.05 1.13
    BRKR F 1.12 1.12
    WST C 1.12 1.01
    TNDM D 5.22 1.00
    PHR F -0.54 0.99
    CNC F -0.02 0.98
    ASND F -0.41 0.88
    VRTX D -0.81 0.84
    ALGN D 0.71 0.72
    TXG F -1.58 0.63
    NTRA A -0.66 0.56
    ACLX C -0.37 0.45
    DNLI D -0.90 0.45
    NRIX C 0.00 0.44
    IRTC C -0.08 0.44
    DAWN D -1.62 0.41
    BNTX D 1.21 0.40
    ANAB F 1.72 0.24

    Represented by ETF Holdings

    Keywords: Medicine S&P 500 Biopharmaceutical Biotechnology Cancer Clinical Medicine Life Sciences Disease Telehealth Telemedicine Diabetes Medical Equipment Medical Technology Nasdaq 100 Endocrine System Endocrinology Infectious Diseases Insulin Organ Systems Autoimmune Disease
    Industries: Biotechnology Medical Devices Diagnostics & Research Medical Instruments & Supplies Health Information Services Health Care Plans Health Information Services Medical Care Facilities Drug Manufacturers - Major

    Recent News for Fidelity Disruptive Medicine ETF & its Holdings

    Date Stock Title
    Nov 21 CNC Meridian Health Plan of Illinois and Liberty Bank and Trust Partner to Create Small Business Loan Program to Support and Empower Diverse and Small Businesses in Illinois
    Nov 21 VEEV Report Reveals 70% of Medtechs Use Manual Processes for Managing Content and Claims
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 UNH 3 Dividend Growth Stocks That Have Increased Their Payouts by More Than 90% in 5 Years
    Nov 21 VEEV Veeva on supporting the data burden in the life sciences sector
    Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 20 PODD Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
    Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
    Nov 20 PEN Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
    Nov 20 IRTC iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
    Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
    Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Nov 20 ALGN Align Technology Has Received CE Mark in Europe for the Invisalign® Palatal Expander System to Address Skeletal and Dental Expansion in Growing Patients, Including Teenage Patients
    Nov 20 TXG If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer
    Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
    Nov 20 INSP Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
    Nov 20 BRKR Bruker jumps as CEO buys $5M company stock
    Nov 20 BRKR Bruker Stock Explodes 10.5% After CEO's $5M Insider Bet
    Nov 20 RMD 3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
    Nov 20 INSP Inspire Medical upped to buy by BoA, improved margins cited
    The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
    Back to the Main FMED Page...